$HCTI
Healthcare Triangle, Inc. Stock $hcti

$hcti Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000160706223000154 Filed on March 28, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$9.838M	$11.29M	$45.89M
YoY Change	-11.02%	22.89%	30.1%
Cost Of Revenue	$8.245M	$9.478M	$34.59M
YoY Change	1.02%	36.97%	39.76%
Gross Profit	$1.593M	$1.814M	$11.30M
YoY Change	-44.96%	-20.06%	7.37%
Gross Profit Margin	16.19%	16.06%	24.62%
Selling, General & Admin	$3.389M	$2.895M	$0.00
YoY Change	9.64%	-13.28%	-100.0%
% of Gross Profit	212.74%	159.59%	0.0%
Research & Development	$539.0K	$2.770M	$5.953M
YoY Change	-49.44%	86.82%	13.17%
% of Gross Profit	33.84%	152.7%	52.7%
Depreciation & Amortization	$874.0K	$910.0K	$3.374M
YoY Change	22.93%	15.44%	137.61%
% of Gross Profit	54.87%	50.17%	29.87%
Operating Expenses	$4.802M	$6.575M	$21.71M
YoY Change	-1.36%	17.21%	36.72%
Operating Profit	-$3.209M	-$4.761M	-$10.42M
YoY Change	62.56%	42.54%	94.33%
Interest Expense	$62.00K	-$83.00K	$212.0K
YoY Change	-487.5%	-4.48%	-137.19%
% of Operating Profit
Other Income/Expense, Net	$12.00K	-$6.000K	$1.081M
YoY Change
Pretax Income	-$3.259M	-$4.850M	-$9.547M
YoY Change	63.77%	41.52%	60.99%
Income Tax	$19.00K	$12.00K	$63.00K
% Of Pretax Income
Net Earnings	-$3.278M	-$4.863M	-$9.610M
YoY Change	63.0%	41.1%	61.51%
Net Earnings / Revenue	-33.32%	-43.07%	-20.94%
Basic Earnings Per Share	-$0.79		-$2.63
Diluted Earnings Per Share	-$0.08	-$0.13	-$0.26
COMMON SHARES
Basic Shares Outstanding	41.71M shares	41.63M shares	3.659M shares
Diluted Shares Outstanding	4.173M shares		3.659M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$267.0K	$1.341M	$1.341M
YoY Change	-82.91%	-24.22%	-24.24%
Cash & Equivalents	$267.0K	$1.341M	$1.341M
Short-Term Investments
Other Short-Term Assets	$661.0K	$816.0K	$816.0K
YoY Change	-52.55%	125.41%	126.67%
Inventory
Prepaid Expenses
Receivables	$5.512M	$5.592M	$5.592M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$6.440M	$7.749M	$7.749M
YoY Change	-33.57%	-34.35%	-34.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$67.00K	$80.00K	$80.00K
YoY Change	-69.41%	8.11%	-68.0%
Goodwill	$1.289M	$1.289M
YoY Change		0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$12.42M	$13.01M	$13.01M
YoY Change	-1.22%	1.6%	1.59%
TOTAL ASSETS
Total Short-Term Assets	$6.440M	$7.749M	$7.749M
Total Long-Term Assets	$12.42M	$13.01M	$13.01M
Total Assets	$18.86M	$20.76M	$20.76M
YoY Change	-15.3%	-15.64%	-15.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.307M	$1.481M	$1.481M
YoY Change	-17.12%	-20.93%	-20.8%
Accrued Expenses		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$2.945M	$2.412M	$2.412M
YoY Change	6.01%	9.19%	-26.46%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.330M	$6.148M	$6.148M
YoY Change	-5.64%	-1.65%	-27.5%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.227M	$2.227M	$2.227M
YoY Change
Total Long-Term Liabilities	$2.227M	$2.227M	$2.227M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.330M	$6.148M	$6.148M
Total Long-Term Liabilities	$2.227M	$2.227M	$2.227M
Total Liabilities	$9.557M	$8.375M	$8.375M
YoY Change	23.03%	-1.21%	-1.24%
SHAREHOLDERS EQUITY
Retained Earnings	-$15.84M	-$12.57M
YoY Change		371.77%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.303M	$12.48M	$12.39M
YoY Change
Total Liabilities & Shareholders Equity	$18.86M	$20.76M	$20.76M
YoY Change	-15.3%	-15.64%	-15.63%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$3.278M	-$4.863M	-$9.610M
YoY Change	63.0%	41.1%	61.51%
Depreciation, Depletion And Amortization	$874.0K	$910.0K	$3.374M
YoY Change	22.93%	15.44%	137.61%
Cash From Operating Activities	-$1.605M	-$2.228M	-$2.600M
YoY Change	-631.46%	-34.78%	-64.33%
INVESTING ACTIVITIES
Capital Expenditures	$2.000K	$14.00K	$3.319M
YoY Change	-110.0%	-100.45%	-206.04%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities	-$2.000K	-$14.00K	-$3.319M
YoY Change	-90.0%	-99.82%	-56.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$5.746M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$533.0K	-561.0K	$5.490M
YoY Change	-208.78%	-104.83%	-64.09%
NET CHANGE
Cash From Operating Activities	-$1.605M	-2.228M	-$2.600M
Cash From Investing Activities	-$2.000K	-14.00K	-$3.319M
Cash From Financing Activities	$533.0K	-561.0K	$5.490M
Net Change In Cash	-$1.074M	-2.803M	-$429.0K
YoY Change	416.35%	-551.28%	-215.95%
FREE CASH FLOW
Cash From Operating Activities	-$1.605M	-$2.228M	-$2.600M
Capital Expenditures	$2.000K	$14.00K	$3.319M
Free Cash Flow	-$1.607M	-$2.242M	-$5.919M
YoY Change	-599.07%	564.3%	42.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001839285
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2022Q4	HCTI	Payroll Protection Program PayrollProtectionProgram		usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021	us-gaap	Other Income OtherIncome		usd
CY2022	HCTI	Warrant Fair Valuation Expenses WarrantFairValuationExpenses		usd
CY2022	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts		usd
CY2022	HCTI	Contingent Consideration ContingentConsideration		usd
CY2022	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates		usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2021	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
CY2021	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes		usd
CY2022	HCTI	Increase In Paycheck Protection Program Loan IncreaseInPaycheckProtectionProgramLoan		usd
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability		usd
CY2022Q4	HCTI	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets		usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	HCTI	Operating Lease Liabiliti OperatingLeaseLiabiliti		usd
CY2022	HCTI	Operating Leases Future Minimum Payment Due Current OperatingLeasesFutureMinimumPaymentDueCurrent		usd
CY2022	HCTI	Operating Leases Future Minimum Payment Due OperatingLeasesFutureMinimumPaymentDue		usd
CY2022	HCTI	Amount Representing Interest AmountRepresentingInterest		usd
CY2022	HCTI	Total Lease Obligation TotalLeaseObligation		usd
CY2022Q4	HCTI	Business Combination Working Capital BusinessCombinationWorkingCapital		usd
CY2022Q4	HCTI	Deferredtaxassetnetofvaluationallowance Deferredtaxassetnetofvaluationallowance		usd
CY2021Q4	HCTI	Deferredtaxassetnetofvaluationallowance Deferredtaxassetnetofvaluationallowance		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	HCTI	Current Federal Tax Expense Benefits CurrentFederalTaxExpenseBenefits		usd
CY2021	HCTI	Current Federal Tax Expense Benefits CurrentFederalTaxExpenseBenefits		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-40903
CY2022	dei	Entity Registrant Name EntityRegistrantName	HEALTHCARE TRIANGLE, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-3559776
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	7901 Stoneridge Drive
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 220
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Pleasanton
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94588
CY2022	dei	City Area Code CityAreaCode	(925)
CY2022	dei	Local Phone Number LocalPhoneNumber	270-4812
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 par value
CY2022	dei	Trading Symbol TradingSymbol	HCTI
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	0	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41709531	shares
CY2022	dei	Auditor Name AuditorName	BF Borgers CPA PC
CY2022	dei	Auditor Firm AuditorFirmId	5041
CY2022	dei	Auditor Location AuditorLocation	Lakewood, CO
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1341000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1770000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5592000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9672000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	816000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	362000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	7749000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	11804000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	74000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	172000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1289000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	1289000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10570000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10458000	usd
CY2022Q4	HCTI	Due From Affiliate DueFromAffiliate	1075000	usd
CY2021Q4	HCTI	Due From Affiliate DueFromAffiliate	816000	usd
CY2022Q4	us-gaap	Assets Assets	20763000	usd
CY2021Q4	us-gaap	Assets Assets	24613000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1481000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1873000	usd
CY2022Q4	HCTI	Warrant Liability WarrantLiability	55000	usd
CY2021Q4	HCTI	Warrant Liability WarrantLiability	55000	usd
CY2021Q4	HCTI	Payroll Protection Program PayrollProtectionProgram	1069000	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	2412000	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	2209000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	176000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2200000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	869000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6148000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6251000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2227000	usd
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2227000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8375000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	8478000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	HCTI	Preferred Stock Voting Shares PreferredStockVotingShares	6000	shares
CY2021Q4	HCTI	Preferred Stock Voting Shares PreferredStockVotingShares	6000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41709531	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41709531	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35260834	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35260834	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	24956000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	18799000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12568000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2664000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	12478000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16135000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20763000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24613000	usd
CY2022	us-gaap	Revenues Revenues	45886000	usd
CY2021	us-gaap	Revenues Revenues	35270000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	34591000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	24748000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5953000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5257000	usd
CY2022	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	6808000	usd
CY2021	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	4761000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5575000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4440000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3374000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1422000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	21711000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	15880000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-10416000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-5358000	usd
CY2022	us-gaap	Other Income OtherIncome	1081000	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-212000	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-567000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9547000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5925000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	63000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	24000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-9610000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-5949000	usd
CY2022	HCTI	Net Income Per Common Sharebasic And Diluted NetIncomePerCommonSharebasicAndDiluted	-0.262
CY2021	HCTI	Net Income Per Common Sharebasic And Diluted NetIncomePerCommonSharebasicAndDiluted	-0.202
CY2022	HCTI	Weighted Average Common Shares Outstanding Basic And Diluted WeightedAverageCommonSharesOutstandingBasicAndDiluted	36740650	shares
CY2021	HCTI	Weighted Average Common Shares Outstanding Basic And Diluted WeightedAverageCommonSharesOutstandingBasicAndDiluted	29427863	shares
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4328000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-5949000	usd
CY2021	HCTI	Shares Issued For Services To Promoter SharesIssuedForServicesToPromoter	114000	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1030000	usd
CY2021	HCTI	Series Super Voting Preferred Stock SeriesSuperVotingPreferredStock	0	usd
CY2021	HCTI	Issue Of Options Isonso IssueOfOptionsIsonso	52000	usd
CY2021	HCTI	Ipo Proceeds IpoProceeds	11796000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	4064000	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	700000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	16135000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-9609000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	125000	usd
CY2022	HCTI	Issue Of Options Isonso IssueOfOptionsIsonso	257000	usd
CY2022	HCTI	Issuance Of Common Stock In Connection With Private Placement IssuanceOfCommonStockInConnectionWithPrivatePlacement	3580000	usd
CY2022	HCTI	Issuance Of Warrants In Connection With Private Placement IssuanceOfWarrantsInConnectionWithPrivatePlacement	2308000	usd
CY2022	HCTI	Common Stock Repurchased CommonStockRepurchased	142000	usd
CY2022	HCTI	Cash Collected On Common Stock Options CashCollectedOnCommonStockOptions	29000	usd
CY2022	HCTI	Prior Period Adjustment PriorPeriodAdjustment	-296000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	12387000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9609000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5950000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3374000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1422000	usd
CY2022	HCTI	Common Stock Issued For Services CommonStockIssuedForServices	124000	usd
CY2021	HCTI	Common Stock Issued For Services CommonStockIssuedForServices	1144000	usd
CY2022	HCTI	Income From Payroll Protection Program IncomeFromPayrollProtectionProgram	1069000	usd
CY2022	HCTI	Interest On Lease Paymentpayroll Protection Program InterestOnLeasePaymentpayrollProtectionProgram	17000	usd
CY2021	HCTI	Interest On Lease Paymentpayroll Protection Program InterestOnLeasePaymentpayrollProtectionProgram	13000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	257000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	52000	usd
CY2021	HCTI	Warrant Fair Valuation Expenses WarrantFairValuationExpenses	55000	usd
CY2021	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	102000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4081000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3276000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	454000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	133000	usd
CY2022	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	259000	usd
CY2021	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	371000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-392000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2477000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1330000	usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	80000	usd
CY2021	HCTI	Contingent Consideration ContingentConsideration	2227000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2600000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7112000	usd
CY2022	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	40000	usd
CY2021	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	79000	usd
CY2022	us-gaap	Increase Decrease In Intangible Assets Current IncreaseDecreaseInIntangibleAssetsCurrent	3279000	usd
CY2021	us-gaap	Increase Decrease In Intangible Assets Current IncreaseDecreaseInIntangibleAssetsCurrent	3050000	usd
CY2021	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	4500000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3319000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7629000	usd
CY2021	HCTI	Increase In Capital IncreaseInCapital	0	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	29000	usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	203000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	294000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	194000	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	181000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5888000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14220000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	142000	usd
CY2021	HCTI	Increase In Paycheck Protection Program Loan IncreaseInPaycheckProtectionProgramLoan	1069000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5490000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15108000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-429000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	367000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1770000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1403000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1341000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1770000	usd
CY2022	us-gaap	Interest Expense InterestExpense	212000	usd
CY2021	us-gaap	Interest Expense InterestExpense	567000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	63000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	24000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_z6Ot0gO66AA5" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_z6K9eHfSJ8kh">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements is in conformity with GAAP which requires us to make estimates, judgments and assumptions that affect the financial statements and the notes thereto. These estimates are based on information available as of the date of the financial statements. On a regular basis, management evaluates these estimates and assumptions. Items subject to such estimates and assumptions include, but are not limited to:</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the standalone selling price for each distinct performance obligation</span></td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the determination of the period of benefit for amortization of deferred costs</span></td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the fair value of assets acquired, and liabilities assumed for business combinations.</span></td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">•</span></td><td style="width: 5pt"/><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share based compensation including warrants</span></td> </tr></table>
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	45886000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	35270000	usd
CY2022	HCTI	Changes Amount ChangesAmount	10616000	usd
CY2022	HCTI	Changes Percentage ChangesPercentage	0.30	pure
CY2022	HCTI	Total Segment Operating Profit TotalSegmentOperatingProfit	-1389000	usd
CY2021	HCTI	Total Segment Operating Profit TotalSegmentOperatingProfit	3635000	usd
CY2022	HCTI	Total Segment Operating Profit Amount Changes TotalSegmentOperatingProfitAmountChanges	-5024000	usd
CY2022	HCTI	Total Segment Operating Profit Percentage Changes TotalSegmentOperatingProfitPercentageChanges	-1.38	pure
CY2022	HCTI	Unallocated Costs UnallocatedCosts	9025000	usd
CY2021	HCTI	Unallocated Costs UnallocatedCosts	8993000	usd
CY2022	HCTI	Less Unallocated Costs Amount Changes LessUnallocatedCostsAmountChanges	32000	usd
CY2022	HCTI	Less Unallocated Costs Percentage Changes LessUnallocatedCostsPercentageChanges	-0	pure
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-10414000	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5358000	usd
CY2022	HCTI	Income From Operations Amount Changes IncomeFromOperationsAmountChanges	-5056000	usd
CY2022	HCTI	Income From Operations Percentage Changes IncomeFromOperationsPercentageChanges	-0.94	pure
CY2022	us-gaap	Other Noncash Income OtherNoncashIncome	1081000	usd
CY2021	us-gaap	Other Noncash Income OtherNoncashIncome	-0	usd
CY2022	HCTI	Other Income Amount Changes OtherIncomeAmountChanges	1081000	usd
CY2022	HCTI	Other Income Percentage Changes OtherIncomePercentageChanges	1	pure
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	211000	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	567000	usd
CY2022	HCTI	Interest Expense Amount Changes InterestExpenseAmountChanges	-356000	usd
CY2022	HCTI	Interest Expense Percentage Changes InterestExpensePercentageChanges	0.63	pure
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-9546000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-5925000	usd
CY2022	HCTI	Net Income Loss Before Income Tax Expenses Amount Changes NetIncomeLossBeforeIncomeTaxExpensesAmountChanges	3621000	usd
CY2022	HCTI	Net Income Loss Before Income Tax Expenses Percentage Changes NetIncomeLossBeforeIncomeTaxExpensesPercentageChanges	-0.61	pure
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	0	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	0	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	5592000	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	9672000	usd
CY2022Q4	HCTI	Warrant Liabilities WarrantLiabilities	55000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2227000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zWKtIVvxUlK6" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zAFPHiEf4Xh2">Concentrations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and trade receivables. Credit risks associated with trade receivables is minimal due to the Company’s customer base which consist of large customer base and ongoing procedures, which monitor the credit worthiness of its customers. For the year ended December 31, 2022 and 2021 sales to five major customers accounted for approximately <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--FiveMajorCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zANO2SXHNH4k" title="Concentration Risk, Percentage">72</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20210101__20211231__srt--MajorCustomersAxis__custom--FiveMajorCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zfTPp4G1JLdk" title="Concentration Risk, Percentage">66</span>% of total revenue respectively. For the year ended December 31, 2022 and year ended December 31, 2021 accounts receivable from five major customers accounted for approximately <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20220101__20221231__srt--MajorCustomersAxis__custom--FiveMajorCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zE12kQJaq4rc" title="Concentration Risk, Percentage">72</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20210101__20211231__srt--MajorCustomersAxis__custom--FiveMajorCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z93Prpic0cPe" title="Concentration Risk, Percentage">73</span>% of the total accounts receivables.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash balances in various financial institutions. The balances are generally insured by the Federal Deposit Insurance Corporation up to $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20221231_z2r4mo3Jpebg" title="Cash, FDIC Insured Amount">250,000</span> (valid through December 31, 2022) per institution.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, and 2021, The Company had $<span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_c20221231_pn3n3" title="Cash Equivalents, at Carrying Value">652</span> and $<span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_c20211231_pn3n3" title="Cash Equivalents, at Carrying Value">719</span>, respectively, of uninsured cash balances. the Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash.</span></p>
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	652000	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	719000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	119000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	80000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	39000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	74000	usd
CY2022	us-gaap	Depreciation Depreciation	35000	usd
CY2021	us-gaap	Depreciation Depreciation	20000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16473000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5903000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10570000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	13194000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2736000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10458000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3167000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1229000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	2108000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	2114000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	2114000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	2114000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive	2114000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	6000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10570000	usd
CY2022	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	180000	usd
CY2021	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	180000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	176000	usd
CY2021	HCTI	Additions Lease Expense AdditionsLeaseExpense	344000	usd
CY2022	HCTI	Finance Cost Accrued During Year FinanceCostAccruedDuringYear	4000	usd
CY2021	HCTI	Finance Cost Accrued During Year FinanceCostAccruedDuringYear	13000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	180000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	181000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	176000	usd
CY2022	HCTI	Schedule Of Balance Sheet Releated To Leases Table Textblock ScheduleOfBalanceSheetReleatedToLeasesTableTextblock	<table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfBalanceSheetReleatedToLeasesTableTextblock_pn3n3_zLigbRmPx06e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 1)"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span id="xdx_8B5_zSN80dOf8o9g" style="display: none">Schedule of balance sheet related to leases</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20221231_zKnCaIYsqKg9" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended December 31, 2022</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--OperatingLeaseRightOfUseAssets_iI_pn3n3_z3mVyCo4qTMe" style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: justify">ROU assets</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0840">—</span> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_zuS3eI08ZLc2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">lease liabilities, included in current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0842">—</span> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_zXWhnRKNfYri" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">lease liabilities, included in long-term liabilities</td><td> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0844">—</span> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--OperatingLeaseLiabiliti_iI_pn3n3_zqkAEd8z3lc1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total lease liabilities</td><td> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">$</td><td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">—</span> </td><td style="text-align: left"> </td></tr> </table>
CY2022	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	180000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	344000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12M
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0475	pure
CY2022Q4	HCTI	Due From Other Related Parties Noncurrents DueFromOtherRelatedPartiesNoncurrents	14063000	usd
CY2021Q4	HCTI	Due From Other Related Parties Noncurrents DueFromOtherRelatedPartiesNoncurrents	13810000	usd
CY2022	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	180000	usd
CY2021	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	180000	usd
CY2022Q4	HCTI	Due From Related Party DueFromRelatedParty	479000	usd
CY2021Q4	HCTI	Due From Related Party DueFromRelatedParty	3710000	usd
CY2022	us-gaap	Increase Decrease In Intangible Assets Current IncreaseDecreaseInIntangibleAssetsCurrent	3279000	usd
CY2021	us-gaap	Increase Decrease In Intangible Assets Current IncreaseDecreaseInIntangibleAssetsCurrent	3050000	usd
CY2022Q4	HCTI	Due From Affiliate DueFromAffiliate	1075000	usd
CY2021Q4	HCTI	Due From Affiliate DueFromAffiliate	816000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	545000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	1936000	usd
CY2022	us-gaap	Proceeds From Sale Of Other Assets1 ProceedsFromSaleOfOtherAssets1	4500000	usd
CY2022	HCTI	Weighted Average Price Of Stock Amount WeightedAveragePriceOfStockAmount	700000	usd
CY2022	HCTI	Unvested Common Stock UnvestedCommonStock	83718	shares
CY2022	HCTI	Earnout Payment EarnoutPayment	2500000	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2209000	usd
CY2022	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2022-03-31
CY2022Q4	us-gaap	Goodwill Gross GoodwillGross	1289000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets	6018000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	1289000	usd
CY2022Q4	us-gaap	Cash Cash	970000	usd
CY2022Q4	HCTI	Business Combination Acquisition Accounts Receivables BusinessCombinationAcquisitionAccountsReceivables	3142000	usd
CY2022Q4	HCTI	Business Combination Acquisition Other Assets Current BusinessCombinationAcquisitionOtherAssetsCurrent	11419000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	758000	usd
CY2022Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	2209000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	679000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities	3646000	usd
CY2022Q4	HCTI	Net Working Capital Acquired NetWorkingCapitalAcquired	7773000	usd
CY2022Q4	HCTI	Total Business Acquisitions Purchase Price TotalBusinessAcquisitionsPurchasePrice	7773000	usd
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.066
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.065
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	5888000	usd
CY2022	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	376822	shares
CY2022Q4	us-gaap	Share Price SharePrice	0.62
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	141000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	4244000	usd
CY2022	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.10	pure
CY2022	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	0	usd
CY2022	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	0	usd
CY2021	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	318000	usd
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.88
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	55000	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1087000	usd
CY2022	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.01	pure
CY2022Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	2414000	usd
CY2021Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	0	usd
CY2021Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	0	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2209000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Maturity Date DebtSecuritiesAvailableForSaleMaturityDate	2022-04-30
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	2209000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2578000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1445000	usd
CY2022Q4	HCTI	Stockbased Compensation StockbasedCompensation	-27000	usd
CY2021Q4	HCTI	Stockbased Compensation StockbasedCompensation	-18000	usd
CY2022Q4	HCTI	Other Income Loan Forgiveness OtherIncomeLoanForgiveness	292000	usd
CY2021Q4	HCTI	Fair Value Of Warrant FairValueOfWarrant	-15000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2843000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1412000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2843000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1412000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	63000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	24000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	63000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	24000	usd
CY2022	HCTI	Total Income Expenses Benefit TotalIncomeExpensesBenefit	63000	usd
CY2021	HCTI	Total Income Expenses Benefit TotalIncomeExpensesBenefit	24000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.01	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2186500	shares
CY2022	HCTI	Incentive Stock Options Iso IncentiveStockOptionsIso	449701	shares
CY2022	HCTI	Nonqualified Stock Options Nso NonqualifiedStockOptionsNso	255000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	603337	shares
CY2022	HCTI	Share Based Compensation Arrangement By Share Based Payment Award Option Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber	1914864	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2085136	shares
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	121000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-9609000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5949000	usd
CY2022	HCTI	Weighted Average Shares Outstanding Used In Basic Per Common Share Computations WeightedAverageSharesOutstandingUsedInBasicPerCommonShareComputations	36740650	shares
CY2021	HCTI	Weighted Average Shares Outstanding Used In Basic Per Common Share Computations WeightedAverageSharesOutstandingUsedInBasicPerCommonShareComputations	29427863	shares
CY2022	HCTI	Weighted Average Basic Diluted Eps WeightedAverageBasicDilutedEps	-0.26	shares
CY2021	HCTI	Weighted Average Basic Diluted Eps WeightedAverageBasicDilutedEps	-0.20	shares

Files In Submission

Name	View Source	Status
0001607062-23-000154-index-headers.html	Edgar Link	pending
0001607062-23-000154-index.html	Edgar Link	pending
0001607062-23-000154.txt	Edgar Link	pending
0001607062-23-000154-xbrl.zip	Edgar Link	pending
ex10_10.htm	Edgar Link	pending
ex10_8.htm	Edgar Link	pending
ex10_9.htm	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hcti-20221231.xsd	Edgar Link	pending
hcti123122form10k.htm	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
hcti-20221231_lab.xml	Edgar Link	unprocessable
hcti-20221231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
hcti123122form10k_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
hcti-20221231_def.xml	Edgar Link	unprocessable
hcti-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HCTI
Healthcare Triangle, Inc. Stock $hcti

2023 Q1 Form 10-K Financial Statement

#000160706223000154 Filed on March 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCTI Healthcare Triangle, Inc. Stock $hcti

2023 Q1 Form 10-K Financial Statement

#000160706223000154 Filed on March 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCTI
Healthcare Triangle, Inc. Stock $hcti